Gates Foundation backs Brazilian measles and rubella vaccine

Brazil-based Bio-Manguinhos is working with the Bill & Melinda Gates Foundation to produce a combined measles and rubella vaccine for developing countries in Africa and other regions. GlaxoSmithKline ($GSK) transferred its MMR technology to Bio-Manguinhos in 2003, but cost and the limited incidence of mumps in some countries has limited uptake in Africa. The measles and rubella vaccine is intended to overcome these barriers. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.